Anton Uvarov
Follow
Get notifications in MyBN when activity occurs.
Anton Uvarov
Non-Executive Director / NeuroScientific Biopharmaceuticals
Dr Anton Uvarov has significant experience as an equity analyst, both domestically and internationally, and is particularly interested in early-stage startups.
Prior to his move to Australia, Dr Uvarov was senior associate at Citigroup Global Markets where he spent two years as a member of New York based healthcare team.
Dr Uvarov has a PhD from University of Manitoba, Canada and an MBA from University of Calgary, Canada.
Prior to his move to Australia, Dr Uvarov was senior associate at Citigroup Global Markets where he spent two years as a member of New York based healthcare team.
Dr Uvarov has a PhD from University of Manitoba, Canada and an MBA from University of Calgary, Canada.
Lists and Charts
Total Shareholder Return as at 31/10/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| th | BlinkLab |
1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | BlinkLab | $37k |
198 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Person Activity
| NEW ROLE: Executive Director, BlinkLab | 13 May 2024 |
| NEWS: Tagged in BlinkLab shares soar on ASX debut | 04 Apr 2024 |
| NEW ROLE: Non-Executive Director, NeuroScientific Biopharmaceuticals | 15 Nov 2022 |
| NEW ROLE: Non-Executive Director, Nutritional Growth Solutions | 13 Nov 2020 |
| REMUNERATION UPDATE: Executive Director, NeuroScientific Biopharmaceuticals | 02 Nov 2020 |
| REMUNERATION UPDATE: Executive Director, NeuroScientific Biopharmaceuticals | 24 Aug 2020 |
| REMUNERATION UPDATE: Executive Director, NeuroScientific Biopharmaceuticals | 30 Jun 2020 |
